Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051178 | 0.83 | SLC1A2 (0.44) | FOLH1SLC1A2KDM4ECYP2C9CYP2C19 | |
| SCHEMBL5053182 | 0.75 | SLC1A2 (0.47) | FOLH1SLC1A2KDM4ECYP2C9CYP2C19 | |
| SCHEMBL7399439 | 0.74 | SLC1A2 (0.46) | SLC1A2KDM4ECYP2C9CYP2C19GRM8 | |
| SCHEMBL5052996 | 0.72 | SLC1A2 (0.44) | FOLH1SLC1A2KDM4ECYP2C9CYP2C19 | |
| SCHEMBL7364671 | 0.72 | SLC1A2 (0.44) | SLC1A2KDM4ECYP2C9CYP2C19GRM8 | |
| SCHEMBL7360984 | 0.71 | GPR84 (0.43) | SLC1A2KDM4ECYP2C9CYP2C19GRM8 | |
| SCHEMBL7392222 | 0.71 | SLC1A2 (0.43) | SLC1A2KDM4ECYP2C9CYP2C19GRM8 | |
| SCHEMBL7357839 | 0.71 | SLC1A2 (0.50) | SLC1A2KDM4ECYP2C9CYP2C19GRM8 | |
| SCHEMBL7364577 | 0.69 | GRM2 (0.41) | SLC1A2KDM4ECYP2C9CYP2C19GRM8 | |
| SCHEMBL7396689 | 0.68 | KMT2A (0.37) | SLC1A2KDM4ECYP2C9CYP2C19GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6313159-B1 | FOR THERAPY OF GLUTAMATE MEDIATED DISEASE, DISORDER SUCH AS: STROKE, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE, SCHIZOPHRENIA, ISCHEMIA, PAIN, DIABETIC NEUROPATHY, TRAUMA, NERVOUS INSULT | GUILFORD PHARMACEUTICALS INC. | 2001-11-06 | — | — | US | claimed |
| WO-2001014390-A2 | METABOTROPIC GLUTAMATE RECEPTOR LIGAND DERIVATIVES AS NAALADase INHIBITORS | GUILFORD PHARMACEUTICALS (US) | 2001-03-01 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-6313159-B1 | FOR THERAPY OF GLUTAMATE MEDIATED DISEASE, DISORDER SUCH AS: STROKE, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE, SCHIZOPHRENIA, ISCHEMIA, PAIN, DIABETIC NEUROPATHY, TRAUMA, NERVOUS INSULT | GUILFORD PHARMACEUTICALS INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001014390-A2 | METABOTROPIC GLUTAMATE RECEPTOR LIGAND DERIVATIVES AS NAALADase INHIBITORS | GUILFORD PHARMACEUTICALS (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885SLC1A2 1629/4885KDM4E 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.